Treatment for urinary incontinence;Tratamiento de la incontinencia urinaria

Atencion Primaria

Volumn 30, Issue 5, 2002, Pages 323-332

  Juarranz Sanz, Margarita ^a   Terron Barbosa R ^a   Roca Guardiola, M ^a   Soriano Llora, T ^a   Villamor Borrego, M ^b   Calvo Alcantara M J ^b  

^a Health Center Canal de Panama   (Spain)

^b Centro Penitenciario Madrid III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; ATROPINE; BACLOFEN; CALCIUM ANTAGONIST; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DESMOPRESSIN; DICYCLOVERINE; DOXAZOSIN; EMEPRONIUM; ESTROGEN; FLAVOXATE; FLURBIPROFEN; IMIPRAMINE; INDOMETACIN; OXYBUTYNIN; PRAZOSIN; PROPANTHELINE BROMIDE; PROSTAGLANDIN INHIBITOR; SALBUTAMOL; TAMSULOSIN; TERAZOSIN; TERBUTALINE; TOLTERODINE; TROSPIUM CHLORIDE;

CONSERVATIVE TREATMENT; DOSE RESPONSE; DRUG EFFICACY; ELDERLY CARE; HUMAN; PATIENT CARE; REVIEW; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT PLANNING; URINARY TRACT FUNCTION; URINE INCONTINENCE;

EID: 0037201478     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0212-6567(02)79035-5     Document Type: Article

References (42)

1. International Continent Society. Standardisation of terminology of lower urinary tract function. Urology 1997;9:237.
2. Badía Llach X, Castro Díaz D, Conejero Sugrañes J. Validez del cuestionario King's Health para la evaluación de la calidad de vida en pacientes con incontinencia urinaria. Med Clin (Barc) 2000;114:647-52.
3. Shaw C, Tansey R, Jackson C, Hyde C, Allan R. Barriers to help seeking in people with urinary symptoms. Family Practice 2001;18:48-52.
4. Cheater FM, Casdeden CM. Epidemiology and classification of urinary incontinence. Bailliére's Best Pract Res Clin Obstet Gynaecol 2000;14:183-205.
5. Hunskaar S, Arnold EP, Burgio K, Diokno AC, Herzog AR, Mallett VT. Epidemiology and natural history of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:301-19.
6. Damian J, Martín-Moreno JM, Lobo F, Bonache J, Cerviño J, Redondo-Márquez L, et al. Prevalence of urinary incontinence among Spanish older people living at home. Eur Urol 1998;34:333-8.
7. Indicadores de la Prestación Farmacéutica en el Sistema Nacional de Salud. Vol 14, año 1996. Madrid: Instituto Nacional de la Salud. Subdirección General de Coordinación Administrativa, 1996.
8. Moore KH. Conservative management for urinary incontinence. Bailliére's Best Pract Res Clin Obstet Gynaecol 2000;14:207-26.
9. Adersson KE. Drug therapy for urinary incontinence. Baillière's Best Pract Res Clin Obstet Gynaecol 2000;14:291-313.
10. Keane DP, O'Sullivan S. Urinary incontinence: Anatomy, physiology and pathophysiology. Bailliére's Best Pract Res Clin Obstet Gynaecol 2000;14:207-26.
11. Couture JA, Valiquette L. Urinary incontinence. Ann Pharmacother 2000;34:646-55.
12. Ruscin JM, Morgenstern NE. Tolterodine use for symptoms of overactive bladder. Ann Pharmacoter 1999;33:1073-82.
13. Steele AC, Kohli N, Mallipeddi P, Karram M. Pharmacologic causes of female incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:106-10.
14. Badía Lluch X, Castro Díaz D, Cabañas Perales L, Peña Outeriño JM, Martínez Agullo E, Conejero Sagrañes J, et al. Elaboración y validación preliminar del cuestionario para la clasificación clínica de la incontinencia urinaria IU-4. Actas Urol Esp 1999;23:565-72.
15. Seim A, Hunskaar S. Female urinary incontinence the role of the general practitioner. Acta Obstet Gynecol Scand 2000;79:1046-51.
16. Bristow SE, Hilton P. Assessment and investigations for urinary incontinence. Baillière's Best Pract Res Clin Obstet Gynaecol 2000; 14:227-49.
17. Verdejo Bravo C, Salinas Casado J, Virseda Chamorro M, Rexach Cano L, Adot Zurbano JM, Ribera Casado JM. Hacia un método simplificado de tipificación de la incontinencia urinaria del anciano, basado en el análisis multivariante de 948 casos. Arch Esp Urol 1999;52:440-50.
18. Bo K, Talseth T. Five year follow up of pelvic floor muscle exercice for treatment of stress urinary incontinence. Clinical and urodynamic assessment. Neurourol Urodyn 1995;14:374-6.
19. Obrien J, Austin M, Sethi P, O'Boyle P. Urinary incontinence: Prevalence, need for treatment, and effectiveness of intervention by nurse. BMJ 1991;303:1308-12.
20. Virseda Chamorro M, Salinas Casado J, Salomón Moh'd S, Esteban Fuertes M, Fernández Ajubita H, Ramírez Fernández JC. Modificación del perfil de presión uretral postelectroestimulación vaginal en el tratamiento de la incontinencia urinaria de esfuerzo. Arch Esp Urol 1997;50:643-7.
21. Fusgen I, Hauri D. Trospium chloride: An effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther 2000;38:223-34.
22. Tropium. Aucum progrés sur l'oxybutynine, mais les prix flambent. Rev Prescr 2001:21:414-5.
23. Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs 1998;55:813-20.
24. Rentzhog L, Staton SL, Cardozo L, Nelson E, Falls M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: A dose-ranging study. Br J Urol 1998;81:42-8.
25. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in overactive bladder. Br J Urol 1999;81:801-10.
26. Drutz HP, Appel RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 1999;10:283-9.
27. Anderson KE, Appell R, Cardozo LD, Chapple C, Drutz HP, Finkbeiner AE, et al. The paharmacological treament of urinary incontinence. BJU Int 1999;84:923-47.
28. Yarquer YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drgs Aging 1995;6:243-6.
29. Moisey CU, Stepheson TP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urol 1980;52:472-5.
30. Cardozo LD, Cooper D, Versi E. Oxybutynin chloride in the management of idiopathic detrusor instability. Neurourol Urodyn 1987;6:256-7.
31. Thüroff JW, Bunke B, Ebner A. Randomized double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propanteheline versus placebo. J Urol 1991;145:813-7.
32. Iselin CE, Schmidlin F, Borst F, Rohner S, Graber PJ. Oxybutynin in the treatment of early detrusor instability after trasurethral resection of the prostate. BrJ Urol 1997;79:915-9.
33. Brendler CB, Radebaugh LC, Mohler JL. Topical oxybutynin chloride for rlaxatlon of dysfunctional bladders. J Urol 1989;141:1350-2.
34. Kaplinsky R, Greenfield S, Wan J, Fera M. Expanded followup of intravesicaloxybutynin use in children with neurogenic bladder. J Urol 1996;156:753-6.
35. Fehrmann Zumpe P, Karbe K, Blessman G. Using flavoxate as primary medication for patients sufffering from urge symptomatology. Int Urogyneccol J 1999;10:91-5.
36. Zubiaur Libano C, Loizaga Iriarte A, Ullate Jaime V, García Sastre E, Arciniega García J, Flores Corral N. Tratamiento médico de la inestabilidad vesical. Nuestra experiencia. Arch Esp Urol 1997;50:633-42.
37. Miller K, Atkin B, Moody ML. Drug therapy for nocturnal enuresis. Drugs 1992;44:47-56.
38. Ruffolo RR, Hieble JP. Adrenoceptor pharmacology: Urogenital applications. Eur Urol 1999;1:17-22.
39. Salinas Casado J, Virseda Chamorro M, Tebla del Pino F, Vázquez Alba D, Adot Zurbano JM. Incontinencia urinaria en la menopausia. Arch Esp Urol 2000;53:349-54.
40. Hilton P, Tweddel AL, Mayne C. Oral and intravaginal estrogens alone and in combination with alpha adrenergic stimulation in genuine stress incontinence. Int Urogynaecol J 1990;12:80-6.
41. Jarvis GJ. Surgery for genuine stress incontinence. BrJ Obstet Gynaecol 1994;101:371-4.
42. Jiménez Calvo J, Hualde Alfaro A, Santiago Gonzeêlez de Garibay A, Lozano Urufiuela F, De Pablo Cárdenas A, et al. TVT (cinta libre de tensión) nueva técnica quirúrgica para el tratamiento de la incontinencia de esfuerzo. Arch Esp Urol 2000;53:9-13.